CN115103677A - Atr抑制剂与parp抑制剂的组合的用途 - Google Patents

Atr抑制剂与parp抑制剂的组合的用途 Download PDF

Info

Publication number
CN115103677A
CN115103677A CN202080096191.XA CN202080096191A CN115103677A CN 115103677 A CN115103677 A CN 115103677A CN 202080096191 A CN202080096191 A CN 202080096191A CN 115103677 A CN115103677 A CN 115103677A
Authority
CN
China
Prior art keywords
optionally substituted
cancer
alkyl
aryl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096191.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·科勒
M·齐默尔曼
A·罗尔斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repair Therapy Co
Original Assignee
Repair Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repair Therapy Co filed Critical Repair Therapy Co
Publication of CN115103677A publication Critical patent/CN115103677A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080096191.XA 2019-12-11 2020-12-11 Atr抑制剂与parp抑制剂的组合的用途 Pending CN115103677A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946876P 2019-12-11 2019-12-11
US62/946876 2019-12-11
PCT/US2020/064662 WO2021119523A1 (en) 2019-12-11 2020-12-11 Use of atr inhibitors in combination with parp inhibitors

Publications (1)

Publication Number Publication Date
CN115103677A true CN115103677A (zh) 2022-09-23

Family

ID=76316464

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096191.XA Pending CN115103677A (zh) 2019-12-11 2020-12-11 Atr抑制剂与parp抑制剂的组合的用途

Country Status (12)

Country Link
US (2) US20210177856A1 (https=)
EP (1) EP4072551A4 (https=)
JP (1) JP2023506787A (https=)
KR (1) KR20220128350A (https=)
CN (1) CN115103677A (https=)
AU (1) AU2020402108A1 (https=)
BR (1) BR112022011426A2 (https=)
CA (1) CA3164203A1 (https=)
CL (1) CL2022001540A1 (https=)
IL (1) IL293810A (https=)
MX (1) MX2022007163A (https=)
WO (1) WO2021119523A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117159725A (zh) * 2023-04-06 2023-12-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
BR112023024942A2 (pt) * 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
CN119212710A (zh) * 2022-04-07 2024-12-27 修复治疗公司 使用atr抑制剂的方法
US20250352539A1 (en) * 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
EP4716756A1 (en) * 2023-05-23 2026-04-01 The Francis Crick Institute Limited Targets for treatment of alt-positive cancers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142231A1 (en) * 2003-12-01 2006-06-29 Alan Ashworth DNA damage repair inhibitors for treatment of cancer
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
WO2018153973A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142231A1 (en) * 2003-12-01 2006-06-29 Alan Ashworth DNA damage repair inhibitors for treatment of cancer
CN106795156A (zh) * 2014-08-04 2017-05-31 拜耳制药股份公司 2‑(吗啉‑4‑基)‑1，7‑萘啶
WO2018153973A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYOUNG KIM，ET AL.: "Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant models", 《CLIN CANCER RES.》, vol. 23, no. 12, pages 3097 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117159725A (zh) * 2023-04-06 2023-12-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法

Also Published As

Publication number Publication date
MX2022007163A (es) 2022-08-25
AU2020402108A1 (en) 2022-07-14
WO2021119523A8 (en) 2021-08-05
EP4072551A4 (en) 2023-11-15
BR112022011426A2 (pt) 2022-08-30
IL293810A (en) 2022-08-01
KR20220128350A (ko) 2022-09-20
US20240350505A1 (en) 2024-10-24
CA3164203A1 (en) 2021-06-17
CL2022001540A1 (es) 2023-01-13
EP4072551A1 (en) 2022-10-19
WO2021119523A1 (en) 2021-06-17
JP2023506787A (ja) 2023-02-20
US20210177856A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
CN115103677A (zh) Atr抑制剂与parp抑制剂的组合的用途
JP2024522736A (ja) がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
ES2957159T3 (es) Estimuladores de SGC fusionados bicíclicos
JP6867295B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
CN104023715B (zh) 激酶抑制剂的副作用降低剂
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
KR20080096657A (ko) 인지 장애의 치료 방법
JP7163180B2 (ja) ３－ヒドロキシ－キナゾリン－２，４－ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用
BR112019005337A2 (pt) terapia combinada
HK1250645A1 (zh) 取代的2，3-二氢咪唑并[1，2-c]喹唑啉类化合物的用途
JPH02121935A (ja) 大脳卒中の治療のための薬剤
CN101123954B (zh) 抗肿瘤剂
WO2020062951A1 (zh) 化合物及其用途
TW202400178A (zh) 使用ａｔｒ抑制劑之方法
ES2749433T3 (es) Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
HK40079144A (en) Use of atr inhibitors in combination with parp inhibitors
JP4232866B2 (ja) 細胞障害抑制剤
EP4656193A1 (en) Pharmaceutical composition for treating tumors
ES2608585T3 (es) Derivados de pirimidilaminobenzamida para su uso en el tratamiento de una enfermedad mieloproliferativa inducida por TEL-PDGFRbeta
HK40107484A (zh) Atr抑制剂与parp抑制剂的组合用於治疗癌症的用途
WO2012123406A1 (en) Novel use of imidazotriazinones
WO2024164089A1 (en) Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
WO2022216930A1 (en) Novel mda-9 antagonist with anti-metastatic potential
ES2341517A1 (es) Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079144

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220923

WD01 Invention patent application deemed withdrawn after publication